ALEC
USDAlector Inc. Common Stock
Echtzeitkurs
Kursdiagramm
Schlüsselkennzahlen
Marktkennzahlen
Eröffnung
$1.400
Hoch
$1.435
Tief
$1.290
Volumen
1.77M
Unternehmensfundamentaldaten
Marktkapitalisierung
133.6M
Branche
Biotechnologie
Land
United States
Handelsstatistiken
Durchschnittliches Volumen
2.62M
Börse
NMS
Währung
USD
52-Wochen-Spanne
Ähnliche Nachrichten
Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce
Alector's Phase 3 trial for FTD-GRN drug, latozinemab, failed the clinical co-primary endpoint. The program is discontinued; Alector cuts 49% of staff.
TD Cowen Downgrades Alector to Hold
TD Cowen analyst Yaron Werber downgrades Alector from Buy to Hold.
Cantor Fitzgerald Downgrades Alector to Neutral
Cantor Fitzgerald analyst Pete Stavropoulos downgrades Alector from Overweight to Neutral.
HC Wainwright & Co. Maintains Buy on Alector, Lowers Price Target to $5
HC Wainwright & Co. analyst Andrew Fein maintains Alector with a Buy and lowers the price target from $10 to $5.
William Blair Downgrades Alector to Market Perform
William Blair analyst Myles Minter downgrades Alector from Outperform to Market Perform.
BTIG Downgrades Alector to Neutral
BTIG analyst Thomas Shrader downgrades Alector from Buy to Neutral.
Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of
Ähnliche Aktien
EAD
Allspring Income Opportunities Fund Common Shares
CXE
MFS High Income Municipal Trust
MMU
Western Asset Managed Municipals Fund Inc.
SQFT
Presidio Property Trust Inc.
ATMU
Atmus Filtration Technologies Inc.
Bleiben Sie auf dem Laufenden
Preisalarme setzen, KI-Analyse-Updates und Echtzeit-Marktnachrichten erhalten.